Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity. by Carroccio, A. et al.
nature publishing group ORIGINAL CONTRIBUTIONS 
C
O
LO
N
/S
M
A
LL
 B
O
W
E
L
1898
The American Journal of GASTROENTEROLOGY VOLUME 107 | DECEMBER 2012   www.amjgastro.com
 INTRODUCTION 
 Celiac disease (CD) prevalence is estimated to be near to 1:100 in 
Western countries ( 1 – 3 ). However, a much higher percentage of 
the general population than this 1 % consider themselves to be suf-
fering from wheat sensitivity (WS) and exclude wheat from their diet 
on the basis of their negative experience aft er eating wheat-contain-
ing foods. Th ese wheat-reactive patients oft en present symptoms 
similar to CD but have negative CD serology and histopathology. 
In most cases, they consult a number of physicians, seeking to  “ reach ” 
a diagnosis of CD but, very oft en, they are considered to be  “ simply ” 
suff ering from irritable bowel syndrome (IBS) ( 4 ). Th e diagnostic 
 “ gold standard ” for WS ought to be the double-blind placebo-
controlled (DBPC) challenge, but this is a quite cumbersome and 
time-consuming method and is therefore very rarely used. 
 In this retrospective study, we report the characteristics of all the 
patients with an IBS-like clinical presentation, who had received a 
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defi nitive diagnosis of WS on the basis of a DBPC challenge in our 
centers in previous years. 
 Aims of the study were: (i) to demonstrate the existence of non-
celiac WS as a defi ned clinical condition and (ii) to identify the 
clinical, serological, and histological characteristics, which could 
distinguish patients with non-CD WS from IBS and from CD 
patients. 
 METHODS 
 We reviewed the clinical charts of all patients with an IBS-like 
clinical presentation attending the outpatient center of the Depart-
ment of Internal Medicine at the University Hospital of Palermo 
and the Department of Internal Medicine of the Hospital of 
Sciacca who had been diagnosed with WS between January 2001 
and June 2011. 
 Inclusion and exclusion criteria 
 We included only patients who fulfi lled the criteria recently 
proposed by the experts ’ meeting on  “ gluten sensitivity ” ( 5,6 ). 
In brief, the patients met all the following inclusion criteria: 
 (i)  IBS-like symptoms defi ned according to the Rome II 
criteria ( 7 ). 
 (ii)  Negative serum anti-transglutaminase (anti-tTG) and 
anti-endomysium (EmA) IgA antibodies. 
 (iii)  Negative duodenal histology (absence of intestinal villous 
atrophy). 
 (iv)  Negative IgE-mediated immuno-allergy tests to wheat 
(skin prick tests and serum-specifi c IgE — RASTs). 
 (v)  Resolution of the symptoms on gluten-free diet and their 
reappearance on DBPC wheat challenge. 
 Additional inclusion criteria were: (i) age   >  18 years; (ii) fol-
low-up duration longer than 8 months aft er the initial diagnosis; 
(iii)   >  2 outpatient visits during the follow-up period. 
 Exclusion criteria were: (i) IgA defi ciency; (ii) self-exclusion of 
wheat from the diet; (iii) lack of DBPC-challenge method in the 
diagnosis. 
 Diagnostic procedures 
 In all cases, WS or multiple food hypersensitivity was diagnosed aft er 
the exclusion of other diagnoses. Consequently, the diagnostic work-
up of the patients may also have included abdominal ultrasonog-
raphy, colonoscopy, histological examination of the recto-colon 
mucosa, small intestine barium examination, and H2 breath test. 
 Immunologic assays and HLA typing for CD 
 All patients underwent serum anti-tTG and EmA IgA, anti-gliadin 
(AGA) IgA and IgG assays performed using commercial kits 
(Eu.tTG. IgA, anti-Gliadin IgA and IgG, and anti-endomisio, 
Eurospital Pharma, Trieste, Italy), and reference values were 
determined as described previously ( 8,9 ). 
 Most patients also underwent EmA assay in the culture medium 
of the intestinal biopsies ( 10,11 ). Patients were also typed for 
HLA-DQ phenotypes by PCR using sequence-specifi c prim-
ers, with a DR and DQ sequence-specifi c primers kit (Unipath 
SpA, Milan, Italy) or a rapid method (DQ-CD Typing Plus by 
BioDiaGene, Palermo, Italy) ( 12 ). 
 Histology studies 
 Duodenal histology .  In accordance with a standard diagnostic 
protocol, four to six biopsy specimens were obtained from the 
second duodenal portion during gastroduodenoscopy. Th e slides 
were stained with hematoxylin and eosin and graded according to 
the standardized scheme reported by Oberhuber  et al. ( 13 ). Th e 
number of intra-epithelial lymphocytes (IELs) per 100 villous epi-
thelial cells was assessed by immunohistochemical staining: CD3  + 
IELs were stained with monoclonal antibody Leu-4. Th e upper 
limit of the reference interval in our laboratory was 25 IELs / 100 
epithelial cells. Th e number of eosinophils (EOS) per high-power 
fi eld ( × 40) was also assessed; the upper limit of the reference 
interval in our laboratory was 60 EOS / 10 high-power fi elds. 
 Other sites of histology examinations .  In all the patients who 
underwent colonoscopy, biopsies were performed in the ileum 
and in diff erent parts of the colon, according to a standard proce-
dure ( 14 ). IELs and EOS were counted at a high-power fi eld ( × 40) 
in cross-sections of 50 crypts randomly selected from each slide 
and these cell numbers were expressed per 100 deep-crypt epithe-
lial cells. Th e EOS count in the lamina propria was expressed as a 
percentage of EOS per 1,000 lamina propria cells per section (fi ve 
sections per biopsy were examined). On the basis of the mean val-
ues   +  2 s.d. observed in the colon biopsies of the control subjects, 
the upper limits of the reference interval in our laboratory were: 
intra-epithelial lymphocytes   <  7, intra-epithelial EOS   <  4, and 
lamina propria EOS   <  9. 
 Allergology tests 
 Specifi c (RAST) IgE and / or skin prick tests to food allergens, as 
well as serum anti- β lactoglobulin IgG assays were performed in 
all patients, as previously described ( 15 ). Many patients under-
went a fl ow cytometric basophil activation test, based on the dem-
onstration of altered membrane phenotypes on allergen-activated 
basophils ( 16 ) (for details see  Supplementary Information ). 
 Elimination diet and DBPC-challenge method 
 At entry to the study, those patients who had self-reduced wheat 
consumption were invited to assume a minimum quantity of 
30  g of wheat daily and were observed for 2 – 4 weeks on a regular 
diet. All patients then commenced a standard elimination diet, 
based on our previous experience ( 14,16 ), with the exclusion 
of wheat, cow ’ s milk, eggs, tomato, and chocolate. Patients self-
reporting food hypersensitivity were also asked to avoid ingestion 
and / or contact with the food(s) causing symptoms. A previously 
validated questionnaire was used to assess self-reported food 
hypersensitivity ( 16 ). 
 Furthermore, food diaries were maintained by the patients 
during the above periods to assess dietary intake and adherence 
to the diet. 
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 Aft er 4 weeks on elimination diet, they underwent DBPC chal-
lenges. Th e challenges were performed with the reintroduction of 
a single food at a time. Details about DBPC challenges are given 
in the  Supplementary Information online. In the case of wheat, 
the DBPC challenge was performed with capsules coded A or B 
containing wheat or xylose, respectively. Capsules A or B were 
given for 2 consecutive weeks and then aft er 1 week of washout the 
patients received the other capsules for another 2 weeks (crossover 
design). 
 During all the phases of the study, including the challenge 
period, the severity of symptoms was recorded: the patients 
completed a 100-mm visual analog scale, with 0 representing no 
symptoms, which assessed overall symptoms and the specifi c 
symptoms they each reported. 
 DBPC challenge for cow ’ s milk proteins was performed with an 
identical method, according to a standard protocol ( 15,16 ), at least 
4 weeks before or aft er wheat challenge and when the visual analog 
scale (VAS) score was   <  10, on elimination diet. 
 Th e challenges were stopped when clinical reactions occurred 
(increase in VAS score   >  30) for at least two consecutive days (onset 
of abdominal discomfort or pain, associated with a change in stool 
frequency and / or appearance). Th e challenges were considered 
positive if the same symptoms, which had been initially presented, 
reappeared aft er their disappearance on elimination diet. 
 Challenges for other foods in patients with suspected multiple 
food hypersensitivity were performed in an open manner. 
 Two control groups were selected. One was composed of 
50 patients with IBS who were classifi ed as not suff ering from 
wheat and food sensitivity, as they resulted negative at the DBPC 
challenges. Th ese subjects were selected at random from those 
who underwent elimination diet and DBPC challenge during the 
same years. 
 Th e second control group was composed of 100 CD patients 
showing gastrointestinal symptoms, selected at random from those 
diagnosed according to standard criteria ( 1 ) during the same years 
and in the same clinical units where the wheat-sensitive patients 
were diagnosed. 
 Statistical analysis 
 Th e sample size was calculated to compare the clinical, laboratory, 
and histological characteristics of the study groups. Choosing an 
error of 0.05 (alpha error) and, considering that the prevalence of 
gluten sensitivity has been reported to be about 6 % in a tertiary 
care center for CD diagnosis ( 6 ), choosing a delta error of 0.03, 
the number of patients to select will be given by the following 
calculation: (1.96 2 × 0.06 × 0.94) / 0.03 2  =  240 ( 17 ). 
 When data distribution was Gaussian, values were expressed 
as mean ± s.d. and diff erences between the two groups were calcu-
lated using the Student ’ s  t -test. Analysis of variance for unpaired 
data was used to compare data with a Gaussian distribution from 
more than two groups. When a signifi cant diff erence was found, 
intergroup comparisons ( post hoc analysis) were made with the 
Bonferroni test. 
 When data distribution was non-Gaussian, values were expressed 
as median (minimum – maximum) and diff erences between the 
two groups were calculated using the Mann – Whitney  U -test. Th e 
Kruskal – Wallis one-way analysis of variance by ranks was used to 
compare data with a non-Gaussian distribution from more than 
two groups. When a signifi cant diff erence was found, intergroup 
comparisons ( post hoc analysis) were made with the Mann – 
Whitney  U -test with a Bonferroni correction. 
 Th e analysis for pairwise data was performed using the Wilcoxon 
rank sum test, as the distribution of data was non-Gaussian. 
 Th e  χ 2 test or Fisher ’ s exact test was used to test the frequencies. 
 SPSS soft ware package (version 16.0; Chicago, IL) was used for 
statistical analysis. 
 Th e study was approved by the Ethics Committee of the 
University Hospital of Palermo. 
 RESULTS 
 During the study period, 920 patients with IBS diagnosis under-
went the elimination diet and subsequent DBPC challenge 
( Figure 1 ); of these, 276 (30 % ) were suff ering from WS as they 
became asymptomatic (VAS score   <  10) on elimination diet and 
showed symptoms again (increase in VAS score   >  30) during the 
DBPC challenge. 
 Seventy patients were diagnosed with WS alone (group 1) and 
two hundred and six were diagnosed with multiple food hypersen-
sitivity, including WS (group 2), as they also reacted to the DBPC 
challenge with cow ’ s milk proteins. Th e patients suff ering from WS 
alone (group 1) showed a clinical reaction to wheat challenge aft er 
a median time of 3 days (range: 3  h to 9 days), whereas those with 
multiple food hypersensitivity (group 2) reacted aft er a median 
of 2.5 days (range: 2  h to 5 days; Mann – Whitney;  P  <  0.01). Ten 
patients in group 1 and thirty-two in group 2 did not complete the 
2-week challenge period due to the severity of symptoms, all when 
they were consuming wheat. No patients reacted to placebo. 
 Figure 2 shows the overall symptom score and the score for 
abdominal pain, bloating, and changes in stool consistency in 
the 276 patients suff ering from WS, considered as a whole group. 
Th e VAS score for each symptom was signifi cantly higher than at 
baseline (on the wheat-free diet) from the fi rst week on the wheat-
containing diet ( P  <  0.0001; Wilcoxon rank sum test) and the values 
further increased at the end of the second week ( P  <  0.0001). On pla-
cebo, there was no signifi cant variation in the VAS score over base-
line aft er weeks 1 and 2. Th e score on the wheat-containing diet was 
signifi cantly higher than on placebo both at the end of the fi rst and 
second weeks into DBPC challenge ( P  <  0.0001; Mann – Whitney). 
 None of the patients suff ering from WS showed increased 
indexes of infl ammation, such as serum C-reactive protein, eryth-
rocyte sedimentation rate, or high white blood cell count, either 
before or aft er the challenges. 
 None of the patients suff ering from WS alone (group 1) reacted 
to the DBPC challenge with cow ’ s milk proteins and no other 
foods caused clinical symptoms. On the contrary, all patients with 
multiple food hypersensitivity (group 2) reacted to the DBPC 
cow ’ s milk protein challenge: symptoms, time, and severity of the 
reaction were similar to those described for the wheat challenge. 
Th e absence of lactose ingestion during the challenge excluded 
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the possibility that lactose intolerance could be responsible for the 
reappearance of symptoms. Furthermore, the patients in group 2 
also showed symptoms when eating several foods, the most 
common being eggs (120 cases) and tomato (112 cases). 
 Table 1 summarizes the demographic and clinical characteris-
tics of the two patient groups suff ering from WS compared with 
the control groups of CD patients and IBS. 
 When we considered the 276 patients suff ering from WS as a 
whole group, they showed an anemia (most sideropenic anemia) 
and weight loss frequency intermediate between the CD and IBS 
control groups and a higher frequency of coexistent atopic dis-
eases, self-reported wheat intolerance, and history of food allergy 
in infancy than both the CD and IBS controls ( Table 2 ). Further-
more, wheat-sensitive patients had undergone a higher number of 
previous gastrointestinal endoscopy examinations (esophagogas-
troduodenoscopy plus colonoscopy) than the CD and IBS controls 
( P  <  0.001 for both groups) during their lives. 
 Table 3 shows the results of the serum AGA, HLA typing, and 
immuno-allergy tests. Th e patients with WS showed a quite high 
frequency of positive serum IgG and IgA AGA. However, the 
allergy assay that tested positive most frequently was the cytomet-
ric basophil activation test. Among the wheat-sensitive patients, a 
small subgroup showed positive EmA assay in the culture medium 
of the duodenal biopsies. 
 Table 4 shows the duodenal and colon histology fi ndings in the 
study groups. In accordance with the exclusion criteria, no patients 
suff ering from WS showed intestinal villous atrophy, whereas all 
the CD patients showed various degrees of villous atrophy. Th ere 
was a very high frequency of duodenal lymphocytosis in patients 
with WS and DQ2- and / or DQ8-positive patients showed a higher 
CD3 number than those DQ2 / DQ8 negatives (49  +  9 vs. 40  +  6 
IEL / 100EC;  t  =  9.6;  P  <  0.0001). Furthermore, WS patients showed 
duodenal intra-epithelial EOS infi ltrate. Lymphocytic infl amma-
tion of the colon mucosa was less frequent than in the duodenum 
in wheat-sensitive patients. On the contrary, EOS infi ltration of the 
colonic mucosa characterized two-third of wheat-sensitive patients 
( Figure 3 ). In patients with multiple food hypersensitivity, the 
Subjects with IBS-like
symptoms according to the
Rome ll criteria
and
fulfilling the criteria for “gluten-
sensitivity”
920 Patients
elegible patient
Four weeks period of
elimination diet and successive
DBPC wheat challenge:
Four weeks period of
elimination diet and successive
DBPC cow’s milk protein
challenge:
Group 1: 70 patients
suffering from wheat
sensitivity alone
Group 2: 206 patients suffering
from multiple food hypersesitivity,
including wheat sensitivity
Control groups: 50 irritable
bowel syndrome patients, and
100 celiac disease patients
276 Suffered from wheat
sensitivity or multiple food
hypersensitivity, including
wheat sensitivity
644 Not suffered from wheat
sensitivity
Excluded
 Figure 1 .  Study design. The clinical charts of 920 patients fulfi ling the Rome II criteria for irritable bowel syndrome (IBS) diagnosis and the criteria for the 
diagnosis of  “ gluten sensitivity ” ( 6 ) were revised. All patients underwent at least 4 weeks of elimination diet (exclusion of wheat, cow ’ s milk and derivatives, 
eggs, tomato, and chocolate). Then they underwent double-blind placebo-controlled (DBPC) wheat challenge and 276 (30 % ) reacted to the challenge. All 
these patients went back on the same elimination diet and after 4 weeks underwent DBPC cow ’ s milk protein challenge. Seventy patients did not react to 
the challenge and subsequently re-introduced all the other foods — except wheat — without any problems: these patients composed group 1 (wheat-sensitive 
patients). Two hundred and six patients also reacted to cow ’ s milk protein challenge: these patients composed group 2 (multiple food-sensitive patients). 
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 Figure 2 .  Changes in symptom severity over baseline during the double-
blind placebo-controlled wheat challenge: 2 weeks on wheat-containing 
diet and 2 weeks on placebo. Mean values   +  s.d. are given. VAS, visual 
analog scale. 
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basophil activation tests ( P  <  0.0001) in the patients with multiple 
food hypersensitivity than in those with WS alone. 
 In patients with multiple food sensitivity, histology showed a 
signifi cantly higher EOS infi ltration of the duodenal and colonic 
mucosa than in patients with WS alone. 
 DISCUSSION 
 Although there is increasing recognition that gluten ingestion can 
also cause various disorders, mainly IBS-like ones outside the cri-
teria for a CD diagnosis ( 4 ), very few studies have been performed 
in this fi eld. 
 WS is frequently perceived by the patients themselves and they 
consult physicians seeking to reach a defi nite diagnosis of CD or 
 “ at least ” of wheat hypersensitivity but this is generally opposed 
as the patients do not fulfi ll the CD diagnostic criteria ( 1 ) and do 
not show laboratory assays documenting an IgE-mediated food 
allergy. On the other hand, the emotional role is known to be 
pivotal in IBS patients ( 18,19 ), consequently the clinical response 
severity of intra-epithelial EOS and lymphocytic infi ltration gradu-
ally decreased from the ileum to the rectum (data not shown). 
 Histologic examination showed a uniformly normal crypt archi-
tecture, normal goblet cell number, and absence of granulomata 
or parasites. 
 Finally,  Table 5 shows the clinical, serologic, and histologic 
characteristics that diff ered between patients with WS alone 
and those with multiple food sensitivity. Patients with WS alone 
(group 1), when compared with patients with multiple food sensi-
tivity (group 2) showed a higher frequency of anemia and weight 
loss, and of the HLA haplotypes DQ2 or DQ8. EmA assay in the 
culture medium of the intestinal biopsies was positive in about 
one-third of the patients with WS alone, whereas none of the 
group 2 patients tested positive. Patients with multiple food sen-
sitivity showed a higher frequency of coexistent atopic disease and 
self-reported wheat intolerance ( P  <  0.0001). 
 Th ere was a signifi cantly higher frequency of positive serum IgG 
anti-betalactoglobulin ( P  <  0.01) and of positive fl ow cytometric 
 Table 1 .  Demographic and IBS-characteristics of the patients suffering from wheat sensitivity alone (group 1), from multiple food hypersen
sitivity,including wheat, (group 2), from CD and from IBS 
  Group 1 ( n =70)  Group 2 ( n =206)  CD patients ( n =100)  IBS controls ( n =50)  P value 
 Sex, M / F ( % of women)  21 / 49 (70 % )  40 / 166 (82 % )  31 / 69 (69 % )  15 / 35 (70 % )  NS 
 IBS Type: Diarrhea / Constipation /
 Alternate bowel mov 
 28 / 14 / 28 (40 / 20 / 40 % )  86 / 51 / 69 (42 / 25 / 33 % )  53 / 20 / 27 (53 / 20 / 27 % )  16 / 14 / 20 (32 / 28 / 40 % )  NS 
 CD, celiac disease; DBPC, double-blind placebo-controlled; F, female; IBS, irritable bowel syndrome; M, male. 
 Wheat hypersensitivity was assessed in all cases by the DBPC challenge method. 
 Table 2 .  Clinical characteristics of the patients suffering from WS ( n =276), CD ( n =100), and IBS ( n =50) 
  WS  CD  IBS  P value 
 Anemia  67 / 276 (24 % )  78 / 100 (78 % )  4 / 50 (8 % )  CD vs. WS 0.0001  
 WS vs. IBS 0.02  
 CD vs. IBS 0.0001 
 Weight loss  94 / 276 (35 % )  52 / 100 (52 % )  2 / 50 (4 % )  CD vs. WS 0.002  
 WS vs. IBS 0.0001  
 CD vs. IBS 0.0001 
 Median (range) duration of symptoms (years)  7 (1 – 40)  4 (1 – 35)  7 (1 – 31)  WS and IBS vs. CD 0.002  
 WS vs. IBS NS 
 Median (range) number of previous endoscopies  3.5 (1 – 6)  1 (1 – 3)  0.5 (0 – 2)  WS vs. CD and IBS  
 0.001  
 CD vs. IBS NS 
 Self-reported wheat intolerance  137 / 276 (50 % )  22 / 100 (22 % )  7 / 50 (14 % )  WS vs. CD and IBS 0.0001  
 CD vs. IBS NS 
 Family history of CD  14 / 276 (5 % )  18 / 100 (18 % )  0 / 50  CD vs. WS 0.01  
 CD vs. IBS 0.005  
 WS vs. IBS NS 
 History of food allergy in infancy  47 / 276 (18 % )  6 / 100 (6 % )  2 / 50 (4 % )  WS vs. CD and IBS 0.01  
 CD vs. IBS NS 
 Coexistent atopic diseases  80 / 276 (29 % )  8 / 100 (8 % )  3 / 50 (6 % )  WS vs. CD and IBS 0.0001  
 CD vs. IBS NS 
 CD, celiac disease; IBS, irritable bowel syndrome; NS, not signifi cant; WS, wheat sensitivity. 
 Notes: (i) Family history of CD indicates a CD diagnosis in a fi rst-degree relative. (ii) History of food allergy in infancy was documented by clinical charts. (iii) Atopic 
diseases were: rhinitis, conjunctivitis, bronchial asthma, atopic dermatitis. 
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to an elimination diet and the use of the DBPC challenge to con-
fi rm the diagnosis of gluten hypersensitivity are suggested ( 20 ). 
 We have used the DBPC-challenge method in numerous studies 
on patients with suspected food hypersensitivity, as it is consid-
ered the gold standard for this diagnosis ( 21,22 ). In this study, we 
reviewed the characteristics of a large group of IBS patients fulfi l-
ing the recent criteria proposed for  “ gluten sensitivity ” who had a 
diagnosis of wheat hypersensitivity following DBPC challenge. 
 Our results clearly showed that a relevant percentage — more 
than one-fourth — of the patients who underwent DBPC wheat 
challenge were really suff ering from WS. 
 As regards the clinical characteristics of WS patients and the 
identifi cation of possible diagnostic markers, our data indicated 
that the presence of anemia and weight loss and a history of food 
allergy in infancy and of coexistent atopic diseases were more fre-
quent in WS patients than in IBS controls. As other studies have not 
shown changes in intestinal permeability and absorption ( 20,23 ), 
it could be hypothesized that the anemia and weight loss may in 
part depend on the self-restricted diet commenced by the patients, 
which excluded many foods. Th e other clinical characteristics are 
very similar to those observed in the allergic patients. Further-
more, the very high frequency of self-reported wheat intolerance, 
 Table 3 .  Number and percentage of positive test results for: serum AGA IgA and IgG, HLA haplotype DQ2 and / or DQ8, serum anti-
betalactoglobulin IgG, and fl ow cytometric basophil activation test in patients with WS and in the control groups (CD and IBS) 
  WS ( n =276)  CD ( n =100)  IBS ( n =50)  P value 
 AGA IgA  110 / 276 (40 % )  72 / 100 (72 % )  5 / 50 (10 % )  WS vs. CD 0.001  
 WS vs. IBS 0.0001  
 CD vs. IBS 0.0001 
 AGA IgG  155 / 276 (55 % )  78 / 100 (78 % )  7 / 50 (14 % )  WS vs. CD 0.01  
 WS vs. IBS 0.0001  
 CD vs. IBS 0.0001 
 DQ2 or DQ8 haplotype  146 / 276 (53 % )  100 / 100 (100 % )  14 / 50 (28 % )  WS vs. CD 0.001  
 WS vs. IBS 0.0001  
 CD vs. IBS 0.0001 
 EmA in biopsy culture 
medium 
 22 / 276 (8 % )  51 / 51 (100 % )  0 / 9 (0 % )  WS vs. CD 0.0001  
 WS vs. IBS, NS  
 CD vs. IBS 0.0001 
 Anti-betalactoglobulin IgG  94 / 276 (35 % )  Not performed  7 / 50 (14 % )   <  0.0005 
 Basophil activation  184 / 276 (66 % )  Not performed  2 / 50 (4 % )   <  0.0001 
 AGA, anti-gliadin; CD, celiac disease; IBS, irritable bowel syndrome; NS, not signifi cant; WS, wheat sensitivity. 
 Notes: not all patients belonging to CD and IBS groups underwent EmA assay in the culture medium. 
 Table 4 .  Duodenal and colon histology fi ndings in patients with WS and in the control groups (celiac disease-CD  – and irritable bowel 
syndrome  – IBS) 
  WS ( n =276)  CD ( n =100)  IBS ( n =50)  P value 
 Duodenal histology 
  CD3  +    >  25 / 100 EC  248 / 276 (90 % )  100 / 100 (100 % )  0 / 9 (0 % )  WS and CD vs. IBS 0.0001 
  CD3  +  number / 100 EC  43 ± 9  68 ± 8  15 ± 5  CD vs. WS and IBS 
 P  <  0.0001  
 WS vs. IBS  P  <  0.0001 
  Eosinophil count per 10 HPF  63 ± 20  38 ± 16  31 ± 12  WS vs. CD and IBS 
 P  <  0.0005 
 Colon histology 
  Presence of lymphoid nodules  84 / 276 (31 % )  Not performed  0 / 35 (0 % )  P  <  0.0001 
  IEL infi ltration  68 / 276 (25 % )  Not performed  8 / 35 (23 % )  NS 
  Eosinophil infi ltration in the lamina propria  165 / 276 (60 % )  Not performed  1 / 35 (3 % )  WS vs. IBS  P  <  0.0002 
  Intra-epithelial eosinophil infi ltration  174 / 276 (63 % )  Not performed  0 / 35 (0 % )  WS vs. IBS  P  <  0.0001 
 CD, celiac disease; EC, enterocytes; HPF, high-power fi eld; IBS, irritable bowel syndrome; IEL, intra-epithelial lymphocytes; NS, not signifi cant; WS, wheat sensitivity. 
 The numbers and percentages of patients showing the various histological fi ndings are given. 
 Notes: Presence of lymphoid nodules indicates the number of patients showing this biopsy fi nding. 
 For the lymphocyte and eosinophil numbers the upper normal limit is indicated in the  “ Methods ” section. 
 Not all IBS patients underwent upper and colon endoscopies: the exact number is given for each examination. 
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 Obviously, other hypotheses must be considered; experimental 
models have demonstrated that gluten sensitization of DQ8 mice 
increases acetylcholine release by the myenteric plexus and this can 
lead to consequent  in vivo dysmotility ( 27 ). In this model, gluten 
did not cause villous atrophy, but there was evidence that coexist-
ent triggers, e.g., intestine-damaging drugs or dysbacteriosis, can 
lead to a more severe intestinal impairment ( 28 ). Clearly, wheat 
antigens may also act in a similar manner. 
 Th e second group of patients with WS — those showing multi-
ple food hypersensitivity — showed characteristics more similar 
to those of allergic rather than of CD patients, although none of 
them tested positive for IgE-based assays. In accordance with the 
 “ allergy hypothesis ” , these patients showed a higher frequency of 
which we observed in our patients, should induce clinicians to pay 
full attention to patient suggestions. 
 As regards the serologic assays, we confi rmed that about half 
of WS patients had positive AGAs ( 20,24 ). More interestingly, the 
 in vitro basophil activation assay confi rmed a high sensitivity for 
WS diagnosis ( 16 ) and further studies would be very useful to con-
fi rm its use, as it seems to be the most accurate marker of WS at 
present. 
 Colon histology evaluation showed intra-epithelial and lamina 
propria infi ltration of EOS in about two-third of cases and this 
fi nding was also frequently observed in the duodenum, together 
with lymphocytosis. Th is histology pattern could be another 
element pointing to a suspected WS diagnosis and the diff use 
ileum-colon involvement could explain why the main symptoms 
in these patients were  “ lower ” and not  “ upper ” ones. 
 However, our data confi rmed the idea that WS is a heterogene-
ous clinical condition, comprising various subgroups of patients 
who have diff erent clinical histories and characteristics. In fact, we 
 “ identifi ed ” at least two distinct kinds of WS: one grouping patients 
with WS alone and another with subjects intolerant to wheat, 
cow ’ s milk protein, and many other foods. Th ese two groups, in 
fact, showed a clear variation in presentation and immunological 
fi ndings, although there was also a signifi cant overlap. 
 Subjects with WS alone showed a higher frequency of the 
DQ2 or DQ8 HLA haplotype, duodenal lymphocytosis was 
seen in 94 % of cases and EmA assay in the culture medium of 
the duodenal biopsies tested positive in one-third of them. 
Although we found negative serum anti-tTG and EmA assays 
and an absence of villous atrophy, a previous study of ours had 
demonstrated that symptomatic patients who produce EmA in 
the duodenal culture can subsequently develop villous atrophy 
when remaining on a gluten-containing diet ( 12 ) and identical 
fi ndings have been reported for serum EmA-positive patients 
with an initial evaluation of normal duodenal histology ( 25 ), as 
well as for patients without villous atrophy but with immunohis-
tochemical evidence of anti-tTG deposits in the duodenal mucosa 
( 26 ). Th ese fi ndings permitted us to hypothesize that a percent-
age of these patients could be predisposed to develop villous atro-
phy — “ overt ” CD — in the future. However, whether these patients 
will eventually develop CD remains to be examined in follow-up 
studies. 
 Table 5 .  Clinical, serologic, and and histologic characteristics in 
patients suffering from wheat sensitivity alone (group 1) and in 
those suffering from multiple foods sensitivity including wheat 
(group 2) 
  Group 1  Group 2  P value 
 Anemia  49 / 70 (70 % )  18 / 206 (9 % )  0.0001 
 Weight loss  32 / 70 (45 % )  62 / 206 (30 % )  0.02 
 Median (range) duration of 
symptoms (years) 
 5.5 years 
(1 – 40) 
 8 years (1 – 30)  0.001 
 Self-reported wheat 
intolerance 
 14 / 70 (20 % )  123 / 206 (60 % )  0.0001 
 Family history of CD  10 / 70 (14 % )  4 / 206 (2 % )  0.0002 
 History of food allergy in 
infancy 
 7 / 70 (10 % )  40 / 206 (19 % )  NS 
 Coexistent atopy  7 / 70 (10 % )  73 / 206 (35 % )  0.0001 
 AGA IgA  28 / 70 (40 % )  82 / 206 (40 % )  NS 
 AGA IgG  21 / 70 (30 % )  134 / 206 (65 % )  0.0001 
 DQ2 or DQ8 haplotype  53 / 70 (75 % )  93 / 206 (45 % )  0.0001 
 EmA in culture medium of 
biopsy 
 22 / 70 (30 % )  0 / 206 (0 % )  0.0001 
 Anti-betalactoglobulin IgG  14 / 70 (20 % )  80 / 206 (39 % )  0.01 
 Basophil activation  28 / 70 (40 % )  166 / 206 (80 % )  0.0001 
 Duodenal histology 
  CD3  +    >  25 / 100 EC  67 / 70 (96 % )  181 / 206 (90 % )  0.0001 
  CD3  +  number / 100 EC  44 ± 8  41 ± 7  NS 
  Eosinophils count per 
10 HPF 
 43 ± 14  70 ± 18  0.0001 
 Colon histology 
  Presence of lymphoid 
nodules 
 14 / 70 (20 % )  70 / 206 (35 % )  0.05 
  IEL infi ltration  17 / 70 (24 % )  51 / 206 (25 % )  NS 
  Eosinophils in the lamina 
propria 
 21 / 70 (30 % )  144 / 206 (70 % )  0.0001 
  Intra-epithelial eosinophil  20 / 70 (28 % )  154 / 206 (75 % )  0.0001 
 AGA, anti-gliadin; CD, celiac disease; EC, enterocytes; HPF, high-power fi eld; 
NS, not signifi cant. 
a b
 Figure 3 .  Histological evidence of signifi cant eosinophil infi ltration in the 
lamina propria of the mucosa of the right colon ( a — hematoxylin and eosin 
(H & E), 40) and lymphoid follicle hyperplasia ( b — H & E, 20) in a patient 
with multiple food hypersensitivity. 
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family and personal history of food allergy and coexistent atopy 
than the other group. Th eir predominant presence in our study 
group probably conditioned the results of the immunology assays 
(positivity of IgG AGA and anti-betalactoglobulin, positivity of 
basophil activation assay) and of the histology studies (mucosal 
EOS infi ltration in the duodenum and colon). Further studies are 
needed to clarify whether this predominant presence of allergic-
like patients can be considered a  “ universal ” characteristic of WS. 
 However, the limitations of our study must be underlined. Th is is 
a retrospective study and the data were not recorded according to a 
predesigned protocol. Although at least four duodenal biopsy sam-
ples were examined, we cannot exclude the possibility that a greater 
number of biopsy samples could have permitted a CD diagnosis in 
some cases ( 29 ). Furthermore, in most of these patients duodenal 
biopsy was not performed in the bulb and this has recently come to 
be considered a recommended biopsy site for CD diagnosis ( 30 ). 
Duodenal IEL infi ltration can be caused by several factors ( 31,32 ) 
and these causes were not all systematically examined. Our series 
is not composed of consecutive patients as we included only sub-
jects who underwent DBPC challenge. Th is did not permit us to 
evaluate the respective incidences of the kinds of WS and could 
have determined a selection bias. As a point of reference, over the 
last year, taking into consideration both patients tested with open 
and DBPC challenge, we have diagnosed, in a single center, 46 new 
CD cases, 15 cases of wheat hypersensitivity alone, and 90 cases 
with multiple food hypersensitivity. Furthermore, in this study we 
did not use gluten but wheat for the challenges. Consequently, we 
cannot exclude the possibility that other components of wheat may 
be responsible for the pictures we describe: i.e., fructans and poorly 
absorbed carbohydrates can induce symptoms by themselves ( 33 ). 
 In conclusion, our data clearly identifi ed a patient population 
suff ering from non-CD WS and described their clinical, serologi-
cal, and histologic characteristics. We also suggest the possibility 
of distinct populations of subjects with WS: one with characteris-
tics more similar to CD and the other with characteristics strongly 
pointing to food allergy. 
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 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE 
 3 It has been reported that about 6 % of people referred to a 
tertiary center for celiac disease are suffering from  “ gluten 
sensitivity ” , but the real existence of this condition is still 
debated. 
 3 Many patients suffering from IBS-like symptoms self-report 
a  “ gluten sensitivity ” and their symptoms improve on a 
gluten-free diet. 
 3 There are no markers of gluten sensitivity (GS) and only one 
study to date, including only a small number of patients, 
has confi rmed the existence of GS as a defi ned clinical 
condition, using the diagnostic gold standard — the double-
blind placebo-controlled food challenge. 
 WHAT IS NEW HERE 
 3 Our results clearly showed that a relevant percentage — one-
third — of our irritable bowel syndrome patients who under-
went DBPC wheat challenge were really suffering from WS. 
 3 WS patients were characterized by frequent self-reported 
wheat intolerance and coexistent atopy and food allergy in 
infancy. 
 3 The main histological characteristic of WS patients was 
eosinophil infi ltration of the duodenal and colon mucosa. 
 3 We suggest that WS is a heterogeneous condition, which 
includes different subgroups of patients. In particular, we 
found that the patients suffering from WS alone were char-
acterized by clinical features more similar to those found 
in CD patients; in contrast, patients suffering from multiple 
food sensitivity were characterized by clinical features 
similar to those found in allergic patients.  
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